Treatment of subnormal bone mineral density
AssigneeGenelabs Technologies, Inc.
InventorKenneth E. Schwartz
Life of this patent
Estimating the term…
Abstract
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
Claims47
A method of treating an individual to increase the individual's bone mineral density (BMD), comprising:
- a) administering a calcitonin-like agent to the individual;
- and
- b) during the period of calcitonin-like agent administration, administering a dehydroepiandrosterone (DHEA)-like agent,
- wherein the amounts of calcitonin- and DHEA-like agents administered are, in combination, effective to increase BMD, and wherein the co-administration of calcitonin- and DHEA-like agents potentiates any increase in BMD achievable by administration of that amount of calcitonin-like agent alone.
The method of claim 9, wherein calcitonin is administered in an average amount of at least about 100 IU per day, and DHEA is administered orally in an amount of at least about 100 mg per day.
A method of potentiating the effect of treatment with a calcitonin-like agent on bone mineral density (BMD) in an individual, comprising:
- during the period of calcitonin-like agent treatment, administering a dehydroepiandrosterone (DHEA) to the individual, in an amount of a least about 50 mg/day.
A method of increasing bone mineral density in an individual undergoing treatment for systemic lupus erythematosus (SLE) by daily administration of a dehydroepiandrosterone (DHEA)-like agent, comprising:
- administering a calcitonin-like agent to the individual, in an average amount of at least about 50 IU per day.
A method for inhibiting bone loss in an individual in need of such treatment, the method comprising administering a therapeutically effective amount of a dehydroepiandrosterone (DHEA)-like agent and an antiresorptive agent selected from the group consisting of a calcitonin-like agent and bisphosphonate to said individual.
A pharmaceutical formulation for inhibiting bone loss in an individual comprising a therapeutically effective amount of a dehydroepiandrosterone (DHEA)-like agent and a therapeutically effective amount of an antiresorptive agent selected from the group consisting of a calcitonin-like agent and bisphosphonate.
Dependencies are inferred from the claim text.